Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia
- PMID: 20194249
- PMCID: PMC3160227
- DOI: 10.1093/schbul/sbq010
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia
Abstract
The National Institute of Mental Health (NIMH)-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Project and related efforts have stimulated the initiation of several studies of pharmacologic treatments for cognitive impairment in schizophrenia. Cognitive remediation may provide an excellent platform for the provision of new learning opportunities and the acquisition of new skills for patients who are engaged in pharmacologic trials to improve cognition. However, it is not clear how a cognitive remediation intervention would be employed in multisite clinical trials. A meeting of experts on cognitive remediation and related methodological topics was convened to address the feasibility and study design issues for the development of a multisite trial of cognitive remediation in schizophrenia called the Cognitive Remediation in the Schizophrenia Trials Network study. This report details the findings from this meeting, which included the following 4 conclusions. (1) A multisite trial of a cognitive remediation intervention using a network of diverse research sites would be of great scientific value. (2) Various interventions could be employed for this multisite trial. (3) Programs that do not address key motivational and interpersonal aspects of cognitive remediation may benefit from supplementation with "bridging groups" that allows patients to meet with others and to apply their newly acquired cognitive skills to everyday life. (4) Before a multisite efficacy trial is initiated, a pilot study could demonstrate the feasibility of conducting a trial using a cognitive remediation intervention.
Similar articles
-
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.J Clin Psychiatry. 2012 Jul;73(7):1016-22. doi: 10.4088/JCP.11m07100. Epub 2012 May 15. J Clin Psychiatry. 2012. PMID: 22687548 Free PMC article. Clinical Trial.
-
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?Schizophr Bull. 2011 Nov;37(6):1209-17. doi: 10.1093/schbul/sbq038. Epub 2010 Apr 21. Schizophr Bull. 2011. PMID: 20410237 Free PMC article.
-
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.Biol Psychiatry. 2004 Sep 1;56(5):301-7. doi: 10.1016/j.biopsych.2004.06.023. Biol Psychiatry. 2004. PMID: 15336511 Review.
-
The MATRICS consensus cognitive battery: what we know 6 years later.Am J Psychiatry. 2014 Nov 1;171(11):1151-4. doi: 10.1176/appi.ajp.2014.14070936. Am J Psychiatry. 2014. PMID: 25756630 No abstract available.
-
Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.Schizophr Bull. 2008 Jul;34(4):656-63. doi: 10.1093/schbul/sbn042. Epub 2008 May 20. Schizophr Bull. 2008. PMID: 18495645 Free PMC article. Review.
Cited by
-
Cognitive training plus a comprehensive psychosocial programme (OPUS) versus the comprehensive psychosocial programme alone for patients with first-episode schizophrenia (the NEUROCOM trial): a study protocol for a centrally randomised, observer-blinded multi-centre clinical trial.Trials. 2011 Feb 9;12:35. doi: 10.1186/1745-6215-12-35. Trials. 2011. PMID: 21306612 Free PMC article. Clinical Trial.
-
A Meta-analysis of Cognitive Remediation for Schizophrenia: Efficacy and the Role of Participant and Treatment Factors.Schizophr Bull. 2021 Jul 8;47(4):997-1006. doi: 10.1093/schbul/sbab022. Schizophr Bull. 2021. PMID: 33772310 Free PMC article.
-
Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches.Psychiatr Clin North Am. 2012 Sep;35(3):683-98. doi: 10.1016/j.psc.2012.06.008. Epub 2012 Jul 15. Psychiatr Clin North Am. 2012. PMID: 22929873 Free PMC article. Review.
-
Compensatory cognitive training for psychosis: who benefits? Who stays in treatment?Schizophr Bull. 2011 Sep;37 Suppl 2(Suppl 2):S55-62. doi: 10.1093/schbul/sbr059. Schizophr Bull. 2011. PMID: 21860048 Free PMC article. Clinical Trial.
-
The clock is ticking on schizophrenia: a study protocol for a translational study integrating phenotypic, genomic, microbiome and biomolecular data to overcome disability.Front Psychiatry. 2024 Oct 30;15:1451678. doi: 10.3389/fpsyt.2024.1451678. eCollection 2024. Front Psychiatry. 2024. PMID: 39540006 Free PMC article.
References
-
- Keefe RSE, Eesley CE, Poe M. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005;57:688–691. - PubMed
-
- Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry. 1991;48:618–624. - PubMed
-
- Harvey PD, Keefe RSE. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectr. 1997;2:1–11.
-
- Heinrichs RW, Zankanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426–444. - PubMed
-
- Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–330. - PubMed